SK Biopharmaceuticals Co., Ltd., a pharmaceutical company, engages in the research and development of drugs for the treatment of central nervous system disorders. The company offers Cenobamate, an anti-seizure medication, for the treatment of epilepsy and Solriamfetol medication. It develops Carisbamate that is in Phase 3 trials to treat lennox-gastaut syndrome; and Relenopride, which is in Phase 2 clinical trials for treatment of rare neurological disease; SKL24741, which is in Phase 1 clinical trials for the treatment of epilepsy; SKL20540, which is in Phase 1 clinical trials for the treatment of schizophrenia; SKL27969 for treatment of advanced solid tumors; SKL13865 clinical trials to treat attention deficit/hyperactivity disorder; and SKL-PSY that is in Phase 1 clinical trials to treat bipolar disorder. The company was founded in 1993 and is headquartered in Seongnam-si, South Korea. SK Biopharmaceuticals Co., Ltd. is a subsidiary of SK Inc.
Metrics to compare | 326030 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship326030PeersSector | |
---|---|---|---|---|
P/E Ratio | 259.5x | −2.1x | −0.7x | |
PEG Ratio | 1.85 | 0.12 | 0.00 | |
Price/Book | 25.9x | 1.5x | 2.6x | |
Price / LTM Sales | 18.9x | 2.3x | 3.2x | |
Upside (Analyst Target) | 4.9% | 30.3% | 43.9% | |
Fair Value Upside | Unlock | 10.5% | 6.5% | Unlock |